相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis
Helei Hou et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Responder of Gefitinib Plus Crizotinib in Osimertinib Failure EGFR-mutant NSCLC-Resistant With Newly Identified STRN-ALK by Next-Generation Sequencing
Chunhua Zhou et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Characterization of acquired receptor tyrosine-kinase fusions as mechanisms of resistance to EGFR tyrosine-kinase inhibitors
Haiyuan Xu et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Alessandro Leonetti et al.
BRITISH JOURNAL OF CANCER (2019)
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
Alexa B. Schrock et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
Claudia Allemani et al.
LANCET (2018)
Clinical analysis by next-generation sequencing for NSCLC patients with &ITMET&IT amplification resistant to osimertinib
Yubo Wang et al.
LUNG CANCER (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report
Ling Zhang et al.
CANCER BIOLOGY & MEDICINE (2018)
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)
Yi-Long Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer
Masayoshi Miyawaki et al.
MOLECULAR CANCER RESEARCH (2017)
Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
Chinami Masuda et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report
Wenhua Liang et al.
BMC CANCER (2016)
Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
Sandra Ortiz-Cuaran et al.
CLINICAL CANCER RESEARCH (2016)
Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy
Paola Ulivi et al.
CLINICAL LUNG CANCER (2016)
Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation
Jin-Ji Yang et al.
CLINICAL CANCER RESEARCH (2014)
Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer
Norihiro Yamaguchi et al.
LUNG CANCER (2014)
Comprehensive Histologic Analysis of ALK-Rearranged Lung Carcinomas
Akihiko Yoshida et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2011)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Jeffrey A. Engelman et al.
CLINICAL CANCER RESEARCH (2008)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
分享论文
